Yüklüyor......
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma
We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3815645/ https://ncbi.nlm.nih.gov/pubmed/22759762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1179/1973947812Y.0000000004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|